Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
NEW YORK, July 19, 2013 /PRNewswire-iReach/ -- Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, a biotech company in Israel, describes a new and unique approach to cancer treatment.
In an allogeneic bone marrow transplant (BMT), the transplanted immune system from a normal donor can mediate a powerful tumor-killing mechanism termed the graft-vs-tumor (GVT) effect. This GVT effect is modulated by T-cells originating from the donor’s marrow. However, these donor T-cells will destroy normal tissue as well as cancer cells. This destruction of normal cells initiates a devastating and often fatal reaction termed graft-vs-host (GVH) disease.
Immunovative Therapies has developed way to separate the potentially curative GVT effect from the lethal GVH complication of BMT procedures. Immunovative Therapies has designed a T-cell infusion that will mirror the effects mediated by the donor immune system onto the host’s immune mechanism. Immunovative Therapies has termed this concept the Mirror Effect.
Dr. Michael Har-Noy states that in the Mirror Effect, donor T-cells are given to a patient and instead of these donor cells initiating a GVT effect, these cells instead cause the patient’s own immune system to attack the cancer. This is an effect termed the host-vs-tumor (HVT) effect and is the mirror image of the GVT mechanism. The patient’s immune system is alerted by the infused foreign donor cells and attempts to reject the foreign tissue, an effect termed the host-vs-graft (HVG). This HVG effect is, in fact, the mirror image of the GVH mechanism. However, unlike the GVH response, the HVG effect is non-toxic to the patient.
The GVT effect is such a powerful mechanism treating cancer because the interaction between the host and donor immune systems facilitates the release of many inflammatory cytokines that signal danger to the patient’s body. Dr. Michael Har-Noy indicates that these danger signals eliminate the cancer’s ability to avoid the attack by the patient’s own immune cells and enable the patient’s immune system to scavenge and kill tumor cells all over the body. The Mirror Effect produces these danger signals as the response to the rejection of a foreign cell infusion (HVG) rather than as an attack of the patient’s normal tissues (GVH).
Therefore, Immunovative Therapies’ Mirror Effect can potentially facilitate the proven curative response of BMT without causing the lethal GVH disease. The Mirror EffectTM of Immunovative Therapies is a completely new concept in cancer treatment.
Dr. Michael Har-Noy indicates that conventional cancer treatments do not have the capacity to identify and eliminate individual malignant cells wherever they reside in a patient’s body. The human immune system is the only mechanism that can do this. Therefore, the ability to harness the power of the immune system to eliminate cancer may be truly curative. The mechanism involved in the Mirror EffectTM technology of Immunovative Therapies represents a breakthrough in both our ability to enable a patient’s immune system to kill tumors and to disrupt a tumor’s ability to avoid the host immune response.
The conception of Immunovative Therapies’ Mirror EffectTM and the development of the Mirror EffectTM mechanism may potentially create a whole industry in medical treatment. Immunovative Therapies is protecting these concepts by using a patent strategy that will translate them into marketable and profitable assets. They continue to develop a patent portfolio that captures the depth, breadth, and complex features of using the Mirror EffectTM to control the immune system and to enable it to treat some of the most complex diseases known.
Thus, Immunovative Therapies’ patent portfolio represents not only protection of a unique cancer treatment method, but has broad implications for creating an entirely new medical industry based on controlling the immune system. This new industry may lead to successful treatments for currently incurable diseases.
About: Immunovative Therapies, founded by Dr. Michael Har-Noy in 2004, is a biotech company in Israel. The company develops unique cancer treatments based on manipulation of the immune system.
Media Contact:Bethany Franklin, Optimizeup.com, 1-800-701-6787, support@optimizeup.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Immunovative Therapies Ltd
Help employers find you! Check out all the jobs and post your resume.
